I like the deal. It gives the company enormous flexibility in negotiating arrangements
with Large Pharmas because they are no longer in a cash starved position. Shorts carping
about the balance sheet will be silenced. Aspire will pay market prices and has agreed not
to engage in any shorting. There will be carping from the group that never wants to see
any dilution. I my view the dilution envolved here is SO SMALL in relation to the benefits
gained by the company that it really DOES NOT MATTER in the long run
bio